1391PImmune-related adverse events (irAEs) and survival (OS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immunotherapy. (23rd October 2018) - Meliàn Sosa, M; Puchades, C; Mendez, J A; Torres, A; Rodrigo, C; Gimeno, G; Rama, E; Martínez-Castillo, A; Caballero Daroqui, J; Gomez Codina, J; Juan-Vidal, O; Lorente, D